Stockreport

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans [Yahoo! Finance]

InflaRx N.V.  (IFRX) 
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
PDF INF904 development will be initially targeted at chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), with initiation of a Phase IIa PK dose-ranging s [Read more]